دورية أكاديمية
[Genetic and non-genetic factors of laboratory resistance to clopidogrel in patients with ischemic stroke].
| العنوان: | [Genetic and non-genetic factors of laboratory resistance to clopidogrel in patients with ischemic stroke]. |
|---|---|
| عنوان ترانسليتريتد: | Geneticheskie i negeneticheskie faktory laboratornoĭ rezistentnosti k klopidogrelu u bol'nykh s ishemicheskim insul'tom. |
| المؤلفون: | Sychev DA; Russian Medical Academy of Continuous Professional Education, Moscow, Russia., Shprakh VV; Irkutsk State Medical Academy of Postgraduate Education - Branch Campus of the Federal State Budgetary Educational Institution of Further Professional Education 'Russian Medical Academy of Continuous Professional Education', Irkutsk, Russia., Kitaeva EY; Irkutsk State Medical Academy of Postgraduate Education - Branch Campus of the Federal State Budgetary Educational Institution of Further Professional Education 'Russian Medical Academy of Continuous Professional Education', Irkutsk, Russia., Mirzaev KB; Russian Medical Academy of Continuous Professional Education, Moscow, Russia., Mickhalevich IM; Irkutsk State Medical Academy of Postgraduate Education - Branch Campus of the Federal State Budgetary Educational Institution of Further Professional Education 'Russian Medical Academy of Continuous Professional Education', Irkutsk, Russia. |
| المصدر: | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2019; Vol. 119 (3. Vyp. 2), pp. 45-52. |
| نوع المنشور: | Journal Article |
| اللغة: | Russian |
| بيانات الدورية: | Publisher: Media Sfera Country of Publication: Russia (Federation) NLM ID: 9712194 Publication Model: Print Cited Medium: Print ISSN: 1997-7298 (Print) Linking ISSN: 19977298 NLM ISO Abbreviation: Zh Nevrol Psikhiatr Im S S Korsakova Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <1995->: Moskva : Media Sfera Original Publication: Moskva : "Meditsina", |
| مواضيع طبية MeSH: | Aryl Hydrocarbon Hydroxylases* , Brain Ischemia*/drug therapy , Clopidogrel*/pharmacology , Cytochrome P-450 Enzyme System*/genetics , Platelet Aggregation Inhibitors*/pharmacology , Stroke*/drug therapy, Female ; Genotype ; Humans ; Male ; Ticlopidine |
| مستخلص: | To identify clinical and pharmacogenetic predictors of the efficacy of clopidogrel in patients with AI based on CYP2C19 and ABCB1 genotyping. MATERIAL AND METHODS: Clinical and laboratory examinations were performed in 121 patients with AI, and CYP2C19 polymorphisms (CYP2C19*2 (G681A, rs4244285), CYP2C19*3 (G363A, rs4986893), CYP2C19*17 (C806T, rs12248560), ABCB1 (C3435T, rs1045642), associated with a disturbance of antiplatelet action of clopidogrel. The carriage of polymorphic markers of the studied genes was determined by the method of polymerase chain reaction in real time. RESULTS AND CONCLUSION: In the group with laboratory resistance to clopidogrel, women prevailed (p<0.0001), atherothrombotic subtype was 80% (p=0.0384), the frequency of obesity ischemic stroke was 60% (p<0.0001). Univariate analysis of variance of CYP2C19 polymorphisms CYP2C19 (CYP2C19*2 (G681A, rs4244285), CYP2C19*3 (G363A, rs4986893), CYP2C19*17 (C806T, rs12248560), ABCB1 (C3435T, rs1045642) in patients with ischemic stroke, demonstrated a significant effect of CYP2C19 genotypes on the indicators of residual reactivity of platelets. |
| فهرسة مساهمة: | Keywords: ABCB1 gene; CYP2C19 gene; clopidogrel; ischemic stroke; pharmacogenetics; polymorphism Local Abstract: [Publisher, Russian] Цель исследования. Выявить клинико-фармакогенетические предикторы эффективности клопидогрела у больных с ишемическим инсультом (ИИ) на основе генотипирования по CYP2C19 и ABCB1. Материал и методы. Проведено клинико-лабораторное обследование 121 больного с ИИ с определением полиморфизмов CYP2C19 (CYP2C19*2 (G681A, rs4244285), CYP2C19*3 (G363A, rs4986893), CYP2C19*17 (C806T, rs12248560) и ABCB1(C3435T, rs1045642), ассоциированных с нарушением антиагрегантного действия клопидогрела. Носительство полиморфных маркеров изучаемых генов определяли методом полимеразной цепной реакции в режиме реального времени. Результаты и заключение. В группе с лабораторной резистентностью к клопидогрелу преобладали женщины (р<0,0001), атеротромботический подтип ИИ составил 80% (р=0,0384), частота ожирения - 60% (р<0,0001). Однофакторный дисперсионный анализ полиморфизмов CYP2C19 (CYP2C19*2 (G681A, rs4244285), CYP2C19*3 (G363A, rs4986893), CYP2C19*17 (C806T, rs12248560) и ABCB1(C3435T, rs1045642) у больных с ИИ продемонстрировал значимое влияние генотипов гена CYP2C19 на показатели остаточной реактивности тромбоцитов. |
| المشرفين على المادة: | 0 (Platelet Aggregation Inhibitors) 9035-51-2 (Cytochrome P-450 Enzyme System) A74586SNO7 (Clopidogrel) EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases) OM90ZUW7M1 (Ticlopidine) |
| تواريخ الأحداث: | Date Created: 20190612 Date Completed: 20190828 Latest Revision: 20190828 |
| رمز التحديث: | 20221213 |
| DOI: | 10.17116/jnevro201911903245 |
| PMID: | 31184624 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1997-7298 |
|---|---|
| DOI: | 10.17116/jnevro201911903245 |